BR112022020322A2 - Método para gerenciar ou diminuir um risco de efeitos adversos em um paciente submetido ao tratamento de distúrbio bipolar i - Google Patents

Método para gerenciar ou diminuir um risco de efeitos adversos em um paciente submetido ao tratamento de distúrbio bipolar i

Info

Publication number
BR112022020322A2
BR112022020322A2 BR112022020322A BR112022020322A BR112022020322A2 BR 112022020322 A2 BR112022020322 A2 BR 112022020322A2 BR 112022020322 A BR112022020322 A BR 112022020322A BR 112022020322 A BR112022020322 A BR 112022020322A BR 112022020322 A2 BR112022020322 A2 BR 112022020322A2
Authority
BR
Brazil
Prior art keywords
adverse effects
bipolar
disorder
risk
undergoing treatment
Prior art date
Application number
BR112022020322A
Other languages
English (en)
Inventor
Ahmad Ateeq
Ahmad Imran
Ahmad Moghisuddin
M Ali Shoukath
Sheikh Saifuddin
Original Assignee
Jina Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jina Pharmaceuticals Inc filed Critical Jina Pharmaceuticals Inc
Publication of BR112022020322A2 publication Critical patent/BR112022020322A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

MÉTODO PARA GERENCIAR OU DIMINUIR UM RISCO DE EFEITOS ADVERSOS EM UM PACIENTE SUBMETIDO AO TRATAMENTO DE DISTÚRBIO BIPOLAR I. Trata-se de um método para gerenciar ou diminuir um risco de efeitos adversos em um paciente submetido ao tratamento de distúrbio bipolar I. O dito método inclui manter a concentração terapeuticamente eficaz de endoxifeno administrando-se uma dose de 2 mg a 16 mg de citrato de endoxifeno em um comprimido com revestimento entérico uma vez ao dia por pelo menos 21 dias. Adicionalmente, efeitos adversos de alteração em funções tireoidianas e trombocitopenia podem ser evitados.
BR112022020322A 2020-04-10 2021-04-09 Método para gerenciar ou diminuir um risco de efeitos adversos em um paciente submetido ao tratamento de distúrbio bipolar i BR112022020322A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063008169P 2020-04-10 2020-04-10
PCT/IB2021/052973 WO2021205405A1 (en) 2020-04-10 2021-04-09 Endoxifen for the treatment of bipolar i disorder

Publications (1)

Publication Number Publication Date
BR112022020322A2 true BR112022020322A2 (pt) 2022-12-13

Family

ID=78022826

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020322A BR112022020322A2 (pt) 2020-04-10 2021-04-09 Método para gerenciar ou diminuir um risco de efeitos adversos em um paciente submetido ao tratamento de distúrbio bipolar i

Country Status (9)

Country Link
US (2) US20210322342A1 (pt)
EP (1) EP4132494A4 (pt)
CN (1) CN115484942A (pt)
AU (1) AU2021252655A1 (pt)
BR (1) BR112022020322A2 (pt)
CA (1) CA3177275A1 (pt)
MX (1) MX2022012659A (pt)
WO (1) WO2021205405A1 (pt)
ZA (1) ZA202211309B (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008048194A1 (en) * 2006-10-20 2008-04-24 Yesilogluj Aysegul Yildiz Use of the protein kinase c inhibitor tamoxifen for the treatment of bipolar disorder
US20090291134A1 (en) * 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
US20110160158A1 (en) * 2008-06-12 2011-06-30 Repligen Corporation Methods of treatment of bipolar disorder
WO2011022292A2 (en) * 2009-08-19 2011-02-24 Lunera Research, Inc. Method of treating bipolar disorder or depression using an antiestrogen

Also Published As

Publication number Publication date
CA3177275A1 (en) 2021-10-14
EP4132494A4 (en) 2024-04-03
ZA202211309B (en) 2023-12-20
CN115484942A (zh) 2022-12-16
US20240115525A1 (en) 2024-04-11
EP4132494A1 (en) 2023-02-15
MX2022012659A (es) 2023-01-16
AU2021252655A1 (en) 2022-10-27
WO2021205405A1 (en) 2021-10-14
US20210322342A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
JP2023113650A5 (pt)
Bishop et al. Diabetic foot ulcers treated with hyperbaric oxygen therapy: a review of the literature
Künzli et al. Impact of preoperative local water-filtered infrared A irradiation on postoperative wound healing: a randomized patient-and observer-blinded controlled clinical trial
Löndahl et al. What is the role of hyperbaric oxygen in the management of diabetic foot disease?
MX2023005455A (es) Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
BR112022020732A2 (pt) Método de dosagem e tratamento de pacientes com um psicodélico, método para determinar uma dose de um psicodélico para um indivíduo, método para definir doses terapêuticas de um psicodélico em ensaios clínicos, método para tratar afecções psiquiátricas em um indivíduo, métodos de terapia, e método para monitorar indivíduos para depressão após tratamento com lsd
BR112021024886A2 (pt) Métodos de tratar a doença de fabry em pacientes com insuficiência renal
BR112022020322A2 (pt) Método para gerenciar ou diminuir um risco de efeitos adversos em um paciente submetido ao tratamento de distúrbio bipolar i
MX2021015228A (es) Metodos y composiciones para mejorar resultados de pacientes con cancer.
sung Rhee et al. Takotsubo cardiomyopathy associated with severe hypocalcemia secondary to idiopathic hypoparathyroidism
CA3177266A1 (en) Endoxifen for the treatment of bipolar i disorder
Chen et al. Improvement of satisfaction in burn patients receiving adjuvant hyperbaric oxygen therapy
BR112018016817A2 (pt) composição farmacêutica e método de tratamento da deficiência do hormônio do crescimento
BR112022020320A2 (pt) Método para manter uma concentração terapeuticamente eficaz de endoxifeno para tratamento de um paciente com distúrbio bipolar i
BR112021016913A2 (pt) Método para tratar doenças relacionadas a tnfa
BR112022027125A2 (pt) Método para tratar um câncer gd2 positivo
UA129745U (uk) Спосіб лікування хворих на бронхіальну астму з ішемічною хворобою серця
Kamgar-Parsi Sleep Disorders and Management
Dhanaram et al. Split skin graft for diabetic ulcers: an analysis
Ahuja et al. Journal of Anesthesia and Clinical Research
MX2023008876A (es) Tratamiento de la apnea del sueño con cannabidiol (cbd).
BR112022015326A2 (pt) Tratamento de menorragia em pacientes com doença de von willebrand severa por administração de vwf recombinante
WO2023081801A3 (en) Methods of treating sickle cell disease with voxelotor
UA132403U (uk) Спосіб лікування хронічних панкреатитів та реабілітації післяопераційних хворих